IRIS Accounts Production v24.3.2.46 10699952 director 1.9.23 31.8.24 31.8.24 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106999522023-08-31106999522024-08-31106999522023-09-012024-08-31106999522022-08-31106999522022-09-012023-08-31106999522023-08-3110699952ns15:EnglandWales2023-09-012024-08-3110699952ns14:PoundSterling2023-09-012024-08-3110699952ns10:Director12023-09-012024-08-3110699952ns10:PrivateLimitedCompanyLtd2023-09-012024-08-3110699952ns10:SmallEntities2023-09-012024-08-3110699952ns10:AuditExempt-NoAccountantsReport2023-09-012024-08-3110699952ns10:SmallCompaniesRegimeForDirectorsReport2023-09-012024-08-3110699952ns10:SmallCompaniesRegimeForAccounts2023-09-012024-08-3110699952ns10:FullAccounts2023-09-012024-08-3110699952ns10:RegisteredOffice2023-09-012024-08-3110699952ns5:CurrentFinancialInstruments2024-08-3110699952ns5:CurrentFinancialInstruments2023-08-3110699952ns5:ShareCapital2024-08-3110699952ns5:ShareCapital2023-08-3110699952ns5:RetainedEarningsAccumulatedLosses2024-08-3110699952ns5:RetainedEarningsAccumulatedLosses2023-08-3110699952ns5:PlantMachinery2023-08-3110699952ns5:ComputerEquipment2023-08-3110699952ns5:PlantMachinery2023-09-012024-08-3110699952ns5:ComputerEquipment2023-09-012024-08-3110699952ns5:PlantMachinery2024-08-3110699952ns5:ComputerEquipment2024-08-3110699952ns5:PlantMachinery2023-08-3110699952ns5:ComputerEquipment2023-08-3110699952ns5:CostValuation2024-08-3110699952ns5:CostValuation2023-08-3110699952ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-3110699952ns5:WithinOneYearns5:CurrentFinancialInstruments2023-08-31
REGISTERED NUMBER: 10699952 (England and Wales)












YELLOWFIN CAPITAL LIMITED
TRADING AS
SOUTH COAST CARDIOLOGY

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 AUGUST 2024






YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


YELLOWFIN CAPITAL LIMITED
TRADING AS SOUTH COAST CARDIOLOGY

COMPANY INFORMATION
FOR THE YEAR ENDED 31 AUGUST 2024







DIRECTOR: A J P Francis





REGISTERED OFFICE: Highland House
Mayflower Close
Chandlers Ford
Eastleigh
Hampshire
SO53 4AR





BUSINESS ADDRESS: 25 St Thomas Street
Winchester
Hampshire
SO23 9HJ





REGISTERED NUMBER: 10699952 (England and Wales)

YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

BALANCE SHEET
31 AUGUST 2024

2024 2023
Notes £ £
FIXED ASSETS
Tangible assets 4 13,992 16,590
Investments 5 100,050 100,050
114,042 116,640

CURRENT ASSETS
Debtors 6 146,704 125,813
Investments 7 100,000 -
Cash at bank 220,948 357,699
467,652 483,512
CREDITORS
Amounts falling due within one year 8 (16,483 ) (21,596 )
NET CURRENT ASSETS 451,169 461,916
TOTAL ASSETS LESS CURRENT
LIABILITIES

565,211

578,556

PROVISIONS FOR LIABILITIES (3,499 ) (368 )
NET ASSETS 561,712 578,188

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 561,612 578,088
561,712 578,188

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

BALANCE SHEET - continued
31 AUGUST 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 January 2025 and were signed by:





A J P Francis - Director


YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024


1. STATUTORY INFORMATION

Yellowfin Capital Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standards applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Preparation of consolidated financial statements
The financial statements contain information about Yellowfin Capital Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Current asset investments
Current asset investments comprise fixed term bank deposits. These investments are classified as a basic financial instrument and are measured at amortised cost.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Computer Equipment - 3 years straight line
Plant & Machinery - 25% on reducing balance

Investments in associates
Investments in associate undertakings are recognised at cost.

Other investments
Other investments are recognised at cost and reviewed for impairments annually.


YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 AUGUST 2024


2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Financial assets
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial assets are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets, which include trade and other receivables and cash and bank balances are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method, unless the arrangement constitutes a financial transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial liabilities
Basic financial liabilities, which include trade and other payables, are initially measured at transaction price and subsequently measured at amortised cost, unless the arrangement constitutes a financing transaction where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of the proceeds received net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - 1 ).

YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 AUGUST 2024


4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£ £ £
COST
At 1 September 2023 33,716 15,046 48,762
Additions 1,149 4,828 5,977
At 31 August 2024 34,865 19,874 54,739
DEPRECIATION
At 1 September 2023 21,478 10,694 32,172
Charge for year 3,343 5,232 8,575
At 31 August 2024 24,821 15,926 40,747
NET BOOK VALUE
At 31 August 2024 10,044 3,948 13,992
At 31 August 2023 12,238 4,352 16,590

5. FIXED ASSET INVESTMENTS
Interest in Other
associate investments Totals
£ £ £
COST
At 1 September 2023
and 31 August 2024 50 100,000 100,050
NET BOOK VALUE
At 31 August 2024 50 100,000 100,050
At 31 August 2023 50 100,000 100,050

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Trade debtors 39,614 36,816
Amounts owed by group undertakings 18,097 18,997
Other debtors 88,993 70,000
146,704 125,813

7. CURRENT ASSET INVESTMENTS
2024 2023
£ £
Fixed term account 100,000 -

YELLOWFIN CAPITAL LIMITED (REGISTERED NUMBER: 10699952)
TRADING AS SOUTH COAST CARDIOLOGY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 AUGUST 2024


8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Trade creditors 3,418 2,520
Taxation and social security 9,666 551
Other creditors 3,399 18,525
16,483 21,596

9. CONTROLLING PARTY

The parent undertaking is Modsarie Holdings Limited.

The registered office of Modsarie Holdings Limited is:

Highland House
Mayflower Close
Chandler's Ford
Eastleigh
Hampshire
SO53 4AR